Clinical trial
PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
NCT04009291 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
- Lead sponsor
- Ascendis Pharma A/S
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 27, 2019
- Completion date
- April 17, 2025
- Enrollment
- 59 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.